MedTrace Logo

Effect of Refnot on Immunity in Cancer Patients

NCT05898451 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 55

Last updated 2023-06-12

No results posted yet for this study

Summary

The study was planned to include disseminated patients with various solid tumors (melanoma, soft tissue sarcoma, breast cancer, colon cancer, etc.). The study drug was administered subcutaneously at a dose of 400,000 IU once a day, 3 times a week (every other day), for 4 weeks. In the absence of disease progression - an additional 4 weeks.

Conditions

Interventions

DRUG

Tumor necrosis factor-thymosin alfa 1 recombinant (TNF-T)

has a direct antitumor effect in vitro and in vivo on various tumor cell lines

DRUG

Tumor necrosis factor-thymosin alfa 1 recombinant (TNF-T) and chemotherapy

Refnot has a direct antitumor effect in vitro and in vivo on various tumor cell lines, chemotherapy has a cytostatic and cytotoxic effect.

Sponsors & Collaborators

  • Refnot-Pharm Ltd

    lead INDUSTRY

Principal Investigators

  • Anatolij D Namgaladze, Master · Refnot-Pharm Ltd

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-06-04
Primary Completion
2011-11-30
Completion
2011-11-30

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05898451 on ClinicalTrials.gov